Drug firm Lupin today said it has inked a pact with Eli Lilly to promote and distribute the US firm's anti-diabetic drugs, including Huminsulin RTM, in India and Nepal.
"Lupin and Eli Lilly have entered into a strategic collaboration to promote and distribute Lilly's Huminsulin range of products, including Huminsulin RTM, Huminsulin NPHTM, Huminsulin 50/50TM, Huminsulin 30/70TM and Humapen Ergo II," Lupin said in a statement.
Lupin's India formulations business will promote and distribute the range of products in India and Nepal, virtually doubling the number of sales representatives behind the diabetes care product, it added.
According to IMS June 2011 data, the total Indian insulin market is valued at Rs 975 crore and Huminsulin is the second biggest brand portfolio in the same.
"Lupin will market and distribute the entire range of Huminsulin brand. The total sales of the brand is close to Rs 125 crore," the company said.
Shares of Lupin today closed at Rs 454.60 on BSE, up 1.15% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app